InvestorsHub Logo
Followers 25
Posts 2345
Boards Moderated 0
Alias Born 06/20/2020

Re: C-20 post# 154049

Monday, 03/22/2021 1:51:44 PM

Monday, March 22, 2021 1:51:44 PM

Post# of 233271

The proof is they showed 24% efficacy in S2C.


Leronlimab did not show 24% efficacy in S2C. It showed 24% efficacy in a small 62 patient slice. 24% efficacy would have been borderline good news if it was the whole trial. 24% efficacy in a slice that represents a small portion of the trial is laughably weak.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News